Paper · 42883756

Identification of a Conserved Temporal Molecular Response Signature to CDK4/6 Inhibition Through Multi-Omics Integration Across Cancer Cell Lines.

Hogger AC and 5 others. Int J Mol Sci, 2026.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Identification of a Conserved Temporal Molecular Response Signature to CDK4/6 Inhibition Through Multi-Omics Integration Across Cancer Cell Lines. Papers, record 42883756. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42883756

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Identification of a Conserved Temporal Molecular Response Signature to CDK4/6 Inhibition Through Multi-Omics Integration Across Cancer Cell Lines.
Journal: Int J Mol Sci
Year: 2026
Publication types: Journal Article
PubMed: https://pubmed.ncbi.nlm.nih.gov/42883756/
DOI: https://doi.org/10.3390/ijms27198507
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13665524/
The journal: https://conductscience.org/library/journal-index/101092791
Revised in PubMed: 2026-10-20

Source PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Hogger AC	Anna C	https://orcid.org/0009-0004-8109-3188
2	Hong T	Ting
3	Mantwill K	Klaus
4	Gaisa N	Nadine
5	Gschwend JE	Jürgen E
6	Nawroth R	Roman

Source PubMed

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Cyclin-Dependent Kinase 4	Major topic
Cyclin-Dependent Kinase 6	Major topic
Protein Kinase Inhibitors	Major topic
Humans
Piperazines
Pyridines
Cell Line, Tumor
Multiomics
Gene Expression Regulation, Neoplastic
Proteomics
Gene Expression Profiling
Signal Transduction
Breast Neoplasms

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References73

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	37,424,386	Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.	Int J Cancer	2023	https://conductscience.org/library/papers/37424386	PubMed
2	38,381,406	Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.	Clin Cancer Res	2024	https://conductscience.org/library/papers/38381406	PubMed
3	28,094,588	Mechanisms and regulation of DNA replication initiation in eukaryotes.	Crit Rev Biochem Mol Biol	2017	https://conductscience.org/library/papers/28094588	PubMed
4	23,708,653	Targeting cell cycle and hormone receptor pathways in cancer.	Oncogene	2013	https://conductscience.org/library/papers/23708653	PubMed
5	36,525,878	DDK promotes DNA replication initiation: Mechanistic and structural insights.	Curr Opin Struct Biol	2023	https://conductscience.org/library/papers/36525878	PubMed
6	22,094,256	A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells.	Cancer Cell	2011	https://conductscience.org/library/papers/22094256	PubMed
7	27,959,613	Palbociclib and Letrozole in Advanced Breast Cancer.	N Engl J Med	2016	https://conductscience.org/library/papers/27959613	PubMed
8	36,813,612	Identification of the KIF and MCM protein families as novel targets for combination therapy with CDK4/6 inhibitors in bladder cancer.	Urol Oncol	2023	https://conductscience.org/library/papers/36813612	PubMed
9	33,761,995	Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.	Breast Cancer Res	2021	https://conductscience.org/library/papers/33761995	PubMed
10	30,579,662	Roles and mechanisms of Kinesin-6 KIF20A in spindle organization during cell division.	Eur J Cell Biol	2019	https://conductscience.org/library/papers/30579662	PubMed

1 to 10 of 73

See all 73 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42883756

GET https://conductscience.org/api/papers/v1/42883756/references?page=2

API reference For AI assistants